Synthetic lethality resulting from combining ATM or ATR inhibition with the increased susceptibility of acid-exposed cancer cells to undergo DNA damages positions tumor acidosis as an attractive predictive biomarker for the clinical use of these drugs. This evidence concerns the gene ATM and cancer.